In PD-1/PD-L1 immune checkpoint inhibitor cancer treatment, IFN-γ is a prognostic marker. The production of IFN-γ is associated with an improved response to immune checkpoint blockade (ICB ...

in terms of IFN-γ production, was seen when ABL403 was tested in combination with the following immune-regulating antibodies: anti-4-1BB (urelumab), anti-PD-1 (pem-brolizumab) and anti-PD-L1 ...

Abstracts are available on the EASL Congress 2025 website at https://www.easlcongress.eu/. The posters are expected to be ...

Solnerstotug showed a 14% response rate and 62% disease control in PD-L1 resistant tumors, surpassing typical expectations. Significant responses were observed in Merkel cell carcinoma and ...

The use of Trodelvy plus Keytruda in patients with previously untreated PD-L1+ metastatic TNBC is investigational, and the safety and efficacy of this use have not been established. The ...

AB-101 (Oral PD-L1 Inhibitor): The Phase 1a/1b trial showed ... mL who were treated with 48 weeks of imdusiran and 24 weeks of IFN,” said Michael J. McElhaugh, Interim President and CEO.